- NASDAQ: INO is set to end the week with a steady upside gain.
- Inovio Pharmaceuticals Inc is still in the COVID-19 vaccine race amid two major advantages.
- The pharma firm has other products in its pipeline which make it a potentially profitable long-term investment.
With Moderna (NASDAQ: MRNA) and Pfizer (NYSE: PFE) try to beat each other with efficacy levels of their COVID-19 vaccines, it may be easy to forget about other efforts such as that of Inovio Pharmaceuticals Inc (NASDAQ: INO). The Plymouth Meeting, Pennsylvania-based pharma firm is also in the race to develop coronavirus immunization – a contest that may have more than one or two winners.
Inovio has received permission to begin a Phase 2/3 trial called Innovate on November 16. While the firm's INO-4800's vaccine candidate needs two doses – like the others – it has other advantages.
First, the inoculation can be stored at room temperature for a full year, easing its distribution and storage. Costs are also likely to be lower. Another factor in its favor – yet currently questioned by the regulator – is the ability to deliver the dose directly through the skin. Inovio's Cellectra 2000 device is needed for administering the vaccine, yet it is simpler than an outright injection.
Inovio's Phase 1 trial has shown that the immunization candidate prompts the creation of both antibodies and T-cells. Even if the first vaccines that Americans and others receive do not come from Inovio, the easy storage and application of this protection could be used as a seasonal boost later on.
Moreover, the company uses its DNA approach to develop other drugs. These include cancer, infectious disease, and human papillomavirus. That makes NASDAQ: INO a potential long-term investment.
Inovio Pharmaceuticals Stock
NASDAQ: INO is quoted at $11.20 in Friday's pre-market trading. Shares are up some 1.63% after dropping by 0.1% on Thursday. Calm trading is relatively new to Inovio's shares, which have ranged between the $8 handle the $12 one during November.
The firm is valued at $1.87 billion, making it a small company in comparison to other pharmaceutical firms. There is substantial room to go toward the 52-week high of $33.79.
More
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
EUR/USD stays near 1.0400 in thin holiday trading
EUR/USD trades with mild losses near 1.0400 on Tuesday. The expectation that the US Federal Reserve will deliver fewer rate cuts in 2025 provides some support for the US Dollar. Trading volumes are likely to remain low heading into the Christmas break.
GBP/USD struggles to find direction, holds steady near 1.2550
GBP/USD consolidates in a range at around 1.2550 on Tuesday after closing in negative territory on Monday. The US Dollar preserves its strength and makes it difficult for the pair to gain traction as trading conditions thin out on Christmas Eve.
Gold holds above $2,600, bulls non-committed on hawkish Fed outlook
Gold trades in a narrow channel above $2,600 on Tuesday, albeit lacking strong follow-through buying. Geopolitical tensions and trade war fears lend support to the safe-haven XAU/USD, while the Fed’s hawkish shift acts as a tailwind for the USD and caps the precious metal.
IRS says crypto staking should be taxed in response to lawsuit
In a filing on Monday, the US International Revenue Service stated that the rewards gotten from staking cryptocurrencies should be taxed, responding to a lawsuit from couple Joshua and Jessica Jarrett.
2025 outlook: What is next for developed economies and currencies?
As the door closes in 2024, and while the year feels like it has passed in the blink of an eye, a lot has happened. If I had to summarise it all in four words, it would be: ‘a year of surprises’.
Best Forex Brokers with Low Spreads
VERIFIED Low spreads are crucial for reducing trading costs. Explore top Forex brokers offering competitive spreads and high leverage. Compare options for EUR/USD, GBP/USD, USD/JPY, and Gold.